the preferred CDMO for pharma and biotech companies
Years of Experience
Investigational New Drug Filings
Molecules Supported Annually
ALCAMI ANNOUNCES THE ACQUISITION OF MASY BIOSERVICES
ACQUISITION TO ADD 375,000 FT² OF CGMP BIOSTORAGE AND PHARMA SUPPORT SERVICES
Wilmington, North Carolina – December 15, 2021 – Alcami Corporation, a leading pharmaceutical and biotech contract development and manufacturing organization (CDMO), announced today it has completed the acquisition of Masy Systems Inc. (“Masy” or “Masy BioServices”), a preferred provider of cGMP Biostorage and pharma support services. The financial terms of the transaction were not disclosed. "The acquisition of Masy adds complementary service offerings and further reinforces Alcami's ambitious growth and expansion initiatives," commented Patrick D. Walsh, Chairman and CEO of Alcami.
DURHAM, N.C. – November 16, 2021 – Alcami, a leading United States-based contract development and manufacturing organization (CDMO), announced today that they have signed a master laboratory services agreement with Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases. With the execution of the agreement, Novavax has immediately secured full-time equivalent (FTE) resources to provide analytical testing support for its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.
TORONTO, October 19, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announces it has entered into an agreement with Alcami Corporation (“Alcami”), a global pharmaceutical contract development and manufacturing organization (CDMO) with extensive experience in cGMP sterile fill-finish products and handling of controlled substances, for the clinical and commercial manufacturing of the Company’s proprietary ketamine products.
CHARLESTON, S.C. – September 29, 2021 - Alcami, a leading United States-based contract development and manufacturing organization (CDMO), announced today an additional $31 million investment to expand its sterile development and manufacturing operation in Charleston, SC. The investment will add a second production line consisting of a vial washer and depyrogenation tunnel, with an isolator filling line containing two lyophilizers, substantially increasing fill-finish and lyophilization capacity. In addition to the new production line, investment has been made in enhanced semi-automated visual inspection equipment to support the additional manufacturing capacity. The new equipment will be qualified and ready for contract cGMP manufacturing in 2022.